Acute infectious pediatric gastroenteritis: beyond oral rehydration therapy.
Worldwide diarrheal diseases are a leading cause of childhood morbidity and mortality. Improvements in gastroenteritis management have reduced the annual number of pediatric deaths attributable to gastroenteritis from 5 million in 1982 to 2 million over 20 years. Recent advances are likely to contribute further to a reduction in morbidity and mortality secondary to acute infectious gastroenteritis. A new generation of vaccines against rotavirus is entering into routine use. Research into antisecretory agents has demonstrated that this class of medications may play a significant role in the future management of acute infectious gastroenteritis. A significant body of literature has recently emerged supporting the use of the antiemetic agent ondansetron. In developing countries, the routine use of zinc is now recommended by many experts, while, in developed countries, the use of probiotic agents has been associated with significant benefits in acute infectious gastroenteritis. Finally, more aggressive intravenous rehydration strategies are being employed; however, at present, limited data from randomized clinical trials are available to support its routine use.
University of Toronto, Division of Pediatric Emergency Medicine, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada. Stephen.freedman@sickkids.ca
Stephen B
SB
Freedman
D000208:Acute Disease; D000284:Administration, Oral; D000818:Animals; D002648:Child; D002675:Child, Preschool; D005440:Fluid Therapy / Q000379:methods* / Q000639:trends; D005759:Gastroenteritis / Q000150:complications / Q000517:prevention & control / Q000628:therapy* / Q000821:virology*; D006801:Humans; D022243:Rotavirus Vaccines / Q000008:administration & dosage / Q000627:therapeutic use
D022243:Rotavirus Vaccines